Graves' Disease in Children: An Update.

Area of Science:

• Pediatric Endocrinology
• Immunology

Background:

• Graves' disease (GD) is the leading cause of hyperthyroidism in pediatric populations.
• Key clinical signs include goiter, suppressed TSH, and elevated FT4/FT3 levels.
• Thyroid receptor antibodies (TRAb) are crucial for specific immunological diagnosis.

Purpose of the Study:

• To outline the diagnostic markers and treatment modalities for pediatric Graves' disease.
• To review current management recommendations and emerging therapies.

Main Methods:

• Review of biochemical profiles and diagnostic criteria for pediatric GD.
• Analysis of established treatment options: anti-thyroid drugs (ATDs), radioiodine, and thyroidectomy.
• Evaluation of novel agents like Rituximab and Teprotumumab in the context of pediatric GD.

Main Results:

• Diagnosis relies on clinical presentation, biochemical assays (TSH, FT4, FT3), and TRAb presence.
• First-line management typically involves a prolonged course of ATDs (3-5+ years).
• Efficacy and safety data for newer drugs (Rituximab, Teprotumumab) in pediatric GD are currently limited.

Conclusions:

• Pediatric Graves' disease requires careful management considering various treatment risks and benefits.
• Extended ATD therapy is the recommended initial approach.
• Further research is needed to establish the role of novel therapies in children with GD.